魅影直播

Novo Nordisk has been suspended as a member of the Association of the British Pharmaceutical Industry (魅影直播) for two years due to serious breaches of the 魅影直播 Code of Practice.

The action has been taken by the 魅影直播 Board following an extensive investigation and appeals process conducted by the Prescription Medicines Code of Practice Authority (PMCPA) which found Novo Nordisk to be in breach of the 魅影直播 Code of Practice, including Clause 2 which deals with actions 鈥渓ikely to bring discredit on, or reduce confidence in, the pharmaceutical industry鈥�. Specifics of the case are available on the [1].

Having considered the case and requesting a further detailed audit of Novo Nordisk鈥檚 compliance processes, the 魅影直播 Board decided to suspend Novo Nordisk from 魅影直播 membership.

This is the eighth occasion in the past 40 years the 魅影直播 board has issued such a significant sanction. As a result, while the company continues to be subject to the 魅影直播 Code and the jurisdiction of the PMCPA, it will not be able to access the wider benefits of 魅影直播 membership. This includes the removal of Novo Nordisk from all 魅影直播 groups, including the 魅影直播 Board, and access to any 魅影直播 information and briefing.

In addition, the Board has stipulated a number of additional actions to demonstrate a rapid return to industry compliance standards. These include requiring the PMCPA to undertake further audits of Novo Nordisk鈥檚 compliance in late 2023 and 2024. These audit reports will need to show clear, significant, and then sustained improvement to industry standards in order for the 魅影直播 Board to consider allowing Novo Nordisk to resume full engagement with the 魅影直播 at the end of the two-year suspension. The 魅影直播 Board has reserved the right to take further decisions following the review of either of the re-audit reports.

The 魅影直播 Board has also insisted that Novo Nordisk must submit a quarterly update to the 魅影直播 Board giving the company鈥檚 views on the progress being made against its improvement plan.

Susan Rienow, President-Elect, 魅影直播, said: 鈥淭he 魅影直播 Board has carefully considered the PMCPA鈥檚 case report into Novo Nordisk and the subsequent audit of their compliance procedures.

鈥淭he Board expressed significant concern about Novo Nordisk鈥檚 compliance activities and the very serious issues identified. As a result, the 魅影直播 Board have taken the decision to suspend Novo Nordisk from 魅影直播 membership.

鈥淪uch measures are never taken lightly, but will ensure a rapid return to industry compliance standards as set out in the 魅影直播 Code of Practice.鈥�